Akari Therapeutics reports Q2 2026 results, keeps AKTX-101 Phase 1 on track for mid-2027
The oncology biotech said it raised $8.6 million in gross proceeds during the quarter while advancing its lead ADC candidate through IND-enabling work.
SEC filing